Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.6 million.

  • Dianthus Therapeutics' Consolidated Net Income fell 4390.1% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 8702.54%. This contributed to the annual value of -$84.5 million for FY2024, which is 9465.33% down from last year.
  • Dianthus Therapeutics' Consolidated Net Income amounted to -$36.6 million in Q3 2025, which was down 4390.1% from -$31.5 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Consolidated Net Income peaked at -$7.1 million during Q1 2023, and registered a low of -$36.6 million during Q3 2025.
  • Moreover, its 4-year median value for Consolidated Net Income was -$14.7 million (2023), whereas its average is -$18.7 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Consolidated Net Income tumbled by 456.58% in 2023 and then tumbled by 16565.83% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Consolidated Net Income stood at -$10.1 million in 2022, then decreased by 4.57% to -$10.5 million in 2023, then crashed by 165.66% to -$27.9 million in 2024, then crashed by 31.17% to -$36.6 million in 2025.
  • Its Consolidated Net Income stands at -$36.6 million for Q3 2025, versus -$31.5 million for Q2 2025 and -$29.4 million for Q1 2025.